Charlotte blood cancer advocate David Wallace shares lessons from six years with undetectable disease ahead of Blood Cancer Awareness Month.
CHARLOTTE, NC, UNITED STATES, August 11, 2026 /EINPresswire.com/ — PV Reporter has announced the release of a patient-focused educational guide detailing how founder David Wallace reached complete molecular remission from polycythemia vera (PV), a rare blood cancer. Issued just before Blood Cancer Awareness Month in September, this guide provides patients with tools to talk to their doctors about driver mutations, treatment objectives, and MPN specialist care.
The guide is accessible at https://pvreporter.com/polycythemia-vera-molecular-remission/.
Wallace received his PV diagnosis in 2009. His blood counts are now normal, and the JAK2 mutation responsible for his condition has been undetectable for over six years. His JAK2 V617F allele burden dropped from approximately 28 percent to undetectable levels—a result termed complete molecular remission. Remission does not mean a cure, and patient outcomes differ significantly.
The new resource outlines Wallace’s journey from phlebotomy to pegylated interferon, and later to a combination therapy involving ruxolitinib. It also describes how research he came across during the 2015 American Society of Hematology annual meeting prompted him to raise the combination approach with his doctor. Throughout his treatment, Wallace developed skin cancer requiring ongoing surveillance, faced infections, and underwent numerous dose adjustments. He continues on a low-dose maintenance regimen.
In his early years with PV, Wallace consulted five different hematologists while searching extensively for a physician with strong MPN expertise and a willingness to engage with current studies. These changes in doctors reflected a broader quest for informed care and were not directly tied to combination therapy. After asking the chief of hematology at his cancer center for “a doctor who knows more about PV than I do,” he was directed to the specialist who still manages his care.
“Most PV patients are never told that deep remission is even on the table,” Wallace said. “Newly diagnosed patients must learn about their illness, understand what each treatment is intended to accomplish and make sure they are seeing a true MPN specialist.”
Published studies indicate that deep molecular responses can be achieved with pegylated interferon alone or in combination with ruxolitinib, though results differ and complete molecular remission continues to be rare. The resource also points patients toward PV Reporter’s free, physician-reviewed MPN Specialist Locator at https://pvreporter.com/mpn-specialists-cancer-treatment-centers/.
About PV Reporter
PV Reporter was established by David Wallace in 2013 with the goal of delivering patient-friendly information on myeloproliferative neoplasms. The site publishes up-to-date MPN research and maintains a physician-reviewed specialist locator as well as a free clinical trial finder. Through PV Reporter and the nonprofit MPN Cancer Connection, Wallace has supported thousands of patients and caregivers across the globe.
David Wallace
PV Reporter
+1 704-323-6771
david@pvreporter.com
